Biogen Inc. (BGEN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

14 CAMBRIDGE CTR CAMBRIDGE, MA 02142

Biogen Inc.'s principal activity is to develop, manufacture and market novel human therapeutic products. The Group currently sells AVONEX (r) for the treatment of relapsing multiple sclerosis (MS) and commencing in 2003, AMEVIVE (r) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. It also has a significant number of ongoing research programs. The products of the Group are marketed in the United States, Europe, Asia and other foreign countries. Vaccines and diagnostic products accounted for 90% of 2002 revenues and Royalties, 10%.

Data based on most recent fiscal year report
Market Cap5.765 Billion Shares Outstanding149.468 Million Avg Volume8.983 Million
1-Yr BETA vs S&P TR Current Ratio3.73 Quick Ratio3.43
View SEC Filings from BGEN instead.
Q3 2019 All Institutions Hedge Funds 1
To trade BGEN now:
No data found for this quarter.
1 hedge funds as identified by whalewisdom.com through public filings.

Funds Holding BGEN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments